U.S. Artificial Intelligence in Biotechnology Market Size, Share and Trends 2025 to 2034

Revenue, 2024

USD 1.76 Bn

Forecast Year, 2034

USD 10.46 Bn

CAGR, 2025 - 2034

19.51%

Report Coverage

U.S.

What is the U.S. Artificial Intelligence in Biotechnology Market Size?

The U.S. artificial intelligence in biotechnology market size is calculated at USD 2.10 billion in 2025 and is predicted to increase from USD 2.51 billion in 2026 to approximately USD 10.46 billion by 2034, expanding at a CAGR of 19.51% from 2025 to 2034. The U.S. artificial intelligence in biotechnology market is driven by AI adoption in drug discovery, precision medicine, and genomics, supported by strong R&D and advanced infrastructure.

Market Highlights

• By offering, the software segment held a significant share of the market in 2024.
• By offering, the services segment is expected to grow at the fastest rate from 2025 to 2034.
• By application, the drug target identification segment held the largest market share in 2024.
• By application, the predictive modeling segment is expected to expand at the fastest rate in the market from 2025 to 2034.
• By usage, the agriculture biotechnology segment held a significant share in 2024.
• By usage, the medical biotechnology segment is expected to grow at the fastest rate from 2025 to 2034.

Transforming Biopharma R&D With AI and Analytics

The U.S. artificial intelligence in biotechnology market has been rapidly evolving as AI technologies reshape the traditional research and development model in the U.S. market. The use of AI algorithms to enhance the accuracy, efficiency, and speed of drug discovery and clinical processes is becoming increasingly popular among biotechnology companies in the United States. Incorporating AI allows scientists to predict molecular interactions, analyze genomic data, and identify potential drug targets more effectively than ever before.

The U.S. is currently experiencing a surge in AI development driven by strong R&D investment, government support, and increasing collaborations between biotech and tech companies. Scientists are using machine learning and deep learning tools to simulate complex biological processes, optimize molecule design, and make better decisions in drug development pipelines. The growing demand for personalized and precise treatments also drives the use of AI in modeling patients and identifying biomarkers.

The Intersection of Data, Talent, and Technology Driving Biotech Innovation

• Strong R&D Investments: U.S. biotech and pharmaceutical companies invest heavily in research and development, which drives the use of AI to find drugs faster, build predictive models, and improve clinical trial outcomes using advanced data analytics and computational biology tools.
• Rising Demand for Personalized Medicine: The increasing demand for personalized treatments and gene-based therapies is driving the use of AI in genomic mapping, biomarker discovery, and personalized drug development, which improves the quality of treatment and medical outcomes.
• Governmental and Regulatory Assistance: The favorable government initiatives, grants, and advantageous FDA arrangements support the integration of AI in biotechnology, compliance, ethical data use, and faster AI-driven research and drug approval.

U.S. Artificial Intelligence in Biotechnology Market Outlook

[[market_outlook]]

Market Scope

U.S. Artificial Intelligence in Biotechnology MarketSegment Insights

[[segment_insights]]

U.S. Artificial Intelligence in Biotechnology Market Value Chain

[[value_chain]]

U.S. Artificial Intelligence in Biotechnology Market Companies

[[market_company]]

Other Companies in the U.S. Artificial Intelligence in Biotechnology Market

• AbCellera : AbCellera uses AI and microfluidics to analyze immune responses and discover therapeutic antibodies at scale. Its proprietary discovery engine integrates single-cell analysis and machine learning, allowing rapid identification of antibody candidates for infectious diseases and oncology.
• Alphabet (DeepMind): DeepMind, part of Alphabet, revolutionized bioinformatics through AlphaFold, an AI system that predicts 3D protein structures with near-experimental accuracy. AlphaFold's open-access database has transformed drug target discovery and protein engineering in biotechnology.
• Amazon Web Services (AWS): AWS provides cloud-based AI and machine learning infrastructure widely used in biotechnology for genomics, drug modeling, and data analysis. Its platforms, including SageMaker and HealthLake, enable scalable AI model training and deployment across biotech research pipelines.
• BenevolentAI: BenevolentAI applies machine learning to knowledge graph-based drug discovery. Its AI platform integrates biomedical data to identify novel drug targets and repurpose existing compounds. The company's research collaborations with AstraZeneca and other pharma leaders enhance its global influence.
• Biogen: Biogen integrates AI across its R&D and clinical pipelines, focusing on neurological and rare diseases. Through partnerships with companies like IBM and Denali Therapeutics, Biogen leverages AI for biomarker discovery, disease progression modeling, and digital diagnostics.
• Exscientia: Exscientia uses AI-driven drug design and precision medicine platforms to automate molecular discovery. The company's integration of active learning and lab automation has led to multiple AI-designed molecules entering clinical trials faster than traditional methods.
• IBM Corporation: IBM's Watson for Drug Discovery uses natural language processing and AI analytics to identify gene-disease-drug relationships. IBM also collaborates with pharmaceutical companies to improve trial optimization and molecular screening efficiency.
• Illumina, Inc.: Illumina is a genomics powerhouse leveraging AI to enhance sequencing accuracy, variant detection, and genomic data interpretation. Its cloud platform Illumina Connected Analytics integrates AI tools for advanced bioinformatics applications in precision medicine.
• Microsoft Corporation: Microsoft's Azure AI for Life Sciences suite provides scalable computational power for genomics and drug discovery. Its collaboration with Adaptive Biotechnologies and the BioGPT model underscores its impact in biomedical natural language processing and bioinformatics.
• NetraMark: NetraMark applies AI-powered predictive modeling to uncover disease subpopulations and treatment response patterns. Its NetraAI platform is used in biotech R&D to optimize clinical trials and accelerate rare disease research.
• NVIDIA Corporation: NVIDIA is the backbone of AI infrastructure for biotech, powering computational biology, molecular simulations, and generative drug design through its Clara Discovery and BioNeMo frameworks. Collaborations with Recursion and Amgen reinforce its leadership in computational biotechnology.
• Sanofi Genzyme: Sanofi Genzyme integrates AI and machine learning in biologics discovery, clinical trial optimization, and digital therapeutics . Its collaborations with Exscientia and Atomwise focus on accelerating small-molecule and biologic design.
• Tempus Labs: Tempus Labs uses AI and real-world clinical data to drive precision oncology and diagnostics. Its vast genomic and clinical data library supports predictive analytics for personalized medicine, drug response modeling, and clinical trial optimization.

Exclusive Analysis on the U.S. Artificial Intelligence in Biotechnology Market

The U.S. artificial intelligence in biotechnology market is experiencing an inflection point, driven by the escalating integration of AI in drug discovery, genomics, molecular modeling, and clinical trial optimization. The convergence of high-performance computing, cloud-based platforms, and advanced machine learning algorithms has enabled biotechnology firms to harness large-scale datasets, streamline R&D pipelines, and enhance predictive accuracy. Strategic alliances between AI technology providers and biopharmaceutical organizations are further catalyzing market growth, creating synergistic pathways that reduce operational inefficiencies and accelerate innovation cycles.

From a market opportunity perspective, the proliferation of AI-powered solutions in precision medicine, biomarker discovery, and multi-omics data integration presents significant upside potential. Tier I incumbents, including NVIDIA, Microsoft, AWS, Alphabet, and IBM, continue to consolidate market leadership by supplying critical computational infrastructure, while Tier II and III players are leveraging AI to carve out niches in drug development, rare disease research, and personalized therapeutics. These dynamics collectively underscore a high-growth environment for both established and emerging players.

Moreover, regulatory impetus, increasing R&D expenditure, and the rising demand for cost-efficient drug development strategies amplify the market's strategic attractiveness. The scalable nature of AI applications, coupled with the potential for recurring revenue models through software licensing, subscriptions, and consultancy services, positions the U.S. AI in biotechnology sector as a fertile landscape for sustained investment, technological disruption, and long-term value creation.

U.S. Artificial Intelligence in Biotechnology MarketSegments Covered in the Report

[[segment_covered]]